Regardless of annual running distance they have lower prevalence of high cholesterol
Paul T. Williams, Ph.D., of Lawrence Berkeley Laboratory, Donner Laboratory in Berkeley, Calif., conducted a study of 62,284 male and 45,040 female participants in the National Runners' Health Study, who gave information on their self-reported medication use, running mileage, age, diet and alcohol intake. Among men, those who ran 0.2 to 0.8 marathons a year were 13 percent less likely to be taking antihypertensive medication compared to non-marathon runners, and were 22 percent and 67 percent less likely to be taking LDL-cholesterol-lowering medications and anti-diabetic medications, respectively, Williams found. In women, there was an association between marathon running and lower use of LDL-cholesterol-lowering and anti-diabetic medication, but this association disappeared when the annual running distance was taken into consideration, the researcher reports. "Among all runners (marathoners and non-marathoners combined), prevalence in the use of all three medications decreased in association with the length of the longest usual run, independent of total annual mileage," Williams writes. "This may be due to the inclusion of longer training runs in preparation for marathons or to genetic or other innate differences between marathon and non-marathon runners."
No comments:
Post a Comment